Last reviewed · How we verify

NCT03200379

Nation-wide Hepatitis C Virus (HCV) Registry in Taiwan

Recruiting now Last updated 8 April 2022
What this trial tests

trial testing directly acting antivirals (DAAs) in Hepatitis C, Chronic in 150,000 participants. Currently enrolling.

Timeline
15 June 2017
Primary endpoint
15 June 2037
15 June 2037

Quick facts

Lead sponsorKaohsiung Medical University Chung-Ho Memorial Hospital
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment150,000
Start date15 June 2017
Primary completion15 June 2037
Estimated completion15 June 2037
Sites1 location across Taiwan

Drugs / interventions tested

Conditions studied

Sponsor

Kaohsiung Medical University Chung-Ho Memorial Hospital

Who can join

Eligibility, any sex, with Hepatitis C, Chronic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To determine the treatment efficacy, safety and long-term outcomes of chronic hepatitis C patients receiving directly acting antivirals in Taiwan

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Hepatitis C, Chronic

Currently open trials in the same condition.

Other Kaohsiung Medical University Chung-Ho Memorial Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03200379.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing